208 related articles for article (PubMed ID: 27853642)
1. RIG-I activation induces the release of extracellular vesicles with antitumor activity.
Daßler-Plenker J; Reiners KS; van den Boorn JG; Hansen HP; Putschli B; Barnert S; Schuberth-Wagner C; Schubert R; Tüting T; Hallek M; Schlee M; Hartmann G; Pogge von Strandmann E; Coch C
Oncoimmunology; 2016; 5(10):e1219827. PubMed ID: 27853642
[TBL] [Abstract][Full Text] [Related]
2. Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cells.
Daßler-Plenker J; Paschen A; Putschli B; Rattay S; Schmitz S; Goldeck M; Bartok E; Hartmann G; Coch C
Int J Cancer; 2019 Apr; 144(7):1645-1656. PubMed ID: 30230526
[TBL] [Abstract][Full Text] [Related]
3. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.
Ponath V; Hoffmann N; Bergmann L; Mäder C; Alashkar Alhamwe B; Preußer C; Pogge von Strandmann E
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671836
[TBL] [Abstract][Full Text] [Related]
4. RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation.
Engel C; Brügmann G; Lambing S; Mühlenbeck LH; Marx S; Hagen C; Horváth D; Goldeck M; Ludwig J; Herzner AM; Drijfhout JW; Wenzel D; Coch C; Tüting T; Schlee M; Hornung V; Hartmann G; Van den Boorn JG
Cancer Immunol Res; 2017 Jun; 5(6):455-467. PubMed ID: 28468914
[TBL] [Abstract][Full Text] [Related]
5. Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53.
Schuldner M; Dörsam B; Shatnyeva O; Reiners KS; Kubarenko A; Hansen HP; Finkernagel F; Roth K; Theurich S; Nist A; Stiewe T; Paschen A; Knittel G; Reinhardt HC; Müller R; Hallek M; von Strandmann EP
Theranostics; 2019; 9(21):6047-6062. PubMed ID: 31534536
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function.
Simhadri VR; Reiners KS; Hansen HP; Topolar D; Simhadri VL; Nohroudi K; Kufer TA; Engert A; Pogge von Strandmann E
PLoS One; 2008; 3(10):e3377. PubMed ID: 18852879
[TBL] [Abstract][Full Text] [Related]
7. Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapy.
Heidegger S; Stritzke F; Dahl S; Daßler-Plenker J; Joachim L; Buschmann D; Fan K; Sauer CM; Ludwig N; Winter C; Enssle S; Li S; Perl M; Görgens A; Haas T; Orberg ET; Göttert S; Wölfel C; Engleitner T; Cortés-Ciriano I; Rad R; Herr W; Giebel B; Ruland J; Bassermann F; Coch C; Hartmann G; Poeck H
Cell Rep Med; 2023 Sep; 4(9):101171. PubMed ID: 37657445
[TBL] [Abstract][Full Text] [Related]
8. Utility of the RIG-I Agonist Triphosphate RNA for Melanoma Therapy.
Helms MW; Jahn-Hofmann K; Gnerlich F; Metz-Weidmann C; Braun M; Dietert G; Scherer P; Grandien K; Theilhaber J; Cao H; Wagenaar TR; Schnurr MM; Endres S; Wiederschain D; Scheidler S; Rothenfußer S; Brunner B; König LM
Mol Cancer Ther; 2019 Dec; 18(12):2343-2356. PubMed ID: 31515294
[TBL] [Abstract][Full Text] [Related]
9. Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity.
Thier B; Zhao F; Stupia S; Brüggemann A; Koch J; Schulze N; Horn S; Coch C; Hartmann G; Sucker A; Schadendorf D; Paschen A
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35697379
[TBL] [Abstract][Full Text] [Related]
10. RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.
Heidegger S; Kreppel D; Bscheider M; Stritzke F; Nedelko T; Wintges A; Bek S; Fischer JC; Graalmann T; Kalinke U; Bassermann F; Haas T; Poeck H
EBioMedicine; 2019 Mar; 41():146-155. PubMed ID: 30852164
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma.
Li Y; Song Y; Li P; Li M; Wang H; Xu T; Yu X; Yu Y; Tai Y; Chen P; Cai X; Wang X; Xiang L; Deng R; Zhang X; Gao L; Wang X; Liu J; Cao F
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152220
[TBL] [Abstract][Full Text] [Related]
12. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells.
Pogge von Strandmann E; Simhadri VR; von Tresckow B; Sasse S; Reiners KS; Hansen HP; Rothe A; Böll B; Simhadri VL; Borchmann P; McKinnon PJ; Hallek M; Engert A
Immunity; 2007 Dec; 27(6):965-74. PubMed ID: 18055229
[TBL] [Abstract][Full Text] [Related]
13. Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy.
Peng B; Nguyen TM; Jayasinghe MK; Gao C; Pham TT; Vu LT; Yeo EYM; Yap G; Wang L; Goh BC; Tam WL; Luo D; Le MT
J Extracell Vesicles; 2022 Apr; 11(4):e12187. PubMed ID: 35430766
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy.
Wang-Bishop L; Wehbe M; Pastora LE; Yang J; Kimmel BR; Garland KM; Becker KW; Carson CS; Roth EW; Gibson-Corley KN; Ulkoski D; Krishnamurthy V; Fedorova O; Richmond A; Pyle AM; Wilson JT
ACS Nano; 2024 May; 18(18):11631-11643. PubMed ID: 38652829
[TBL] [Abstract][Full Text] [Related]
15. Multifunctional antitumor molecule 5'-triphosphate siRNA combining glutaminase silencing and RIG-I activation.
Meng G; Xia M; Xu C; Yuan D; Schnurr M; Wei J
Int J Cancer; 2014 Apr; 134(8):1958-71. PubMed ID: 23921958
[TBL] [Abstract][Full Text] [Related]
16. The Antitumor Effect of Heparin is not Mediated by Direct NK Cell Activation.
Rossi GR; Gonçalves JP; McCulloch T; Delconte RB; Hennessy RJ; Huntington ND; Trindade ES; Souza-Fonseca-Guimaraes F
J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32824699
[TBL] [Abstract][Full Text] [Related]
17. Tumor-induced apoptosis of human IL-2-activated NK cells: role of natural cytotoxicity receptors.
Poggi A; Massaro AM; Negrini S; Contini P; Zocchi MR
J Immunol; 2005 Mar; 174(5):2653-60. PubMed ID: 15728472
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming.
Zhu L; Kalimuthu S; Oh JM; Gangadaran P; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
Biomaterials; 2019 Jan; 190-191():38-50. PubMed ID: 30391801
[TBL] [Abstract][Full Text] [Related]
19. Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma.
Glas M; Coch C; Trageser D; Dassler J; Simon M; Koch P; Mertens J; Quandel T; Gorris R; Reinartz R; Wieland A; Von Lehe M; Pusch A; Roy K; Schlee M; Neumann H; Fimmers R; Herrlinger U; Brüstle O; Hartmann G; Besch R; Scheffler B
Stem Cells; 2013 Jun; 31(6):1064-74. PubMed ID: 23390110
[TBL] [Abstract][Full Text] [Related]
20. Covalent Polymer-RNA Conjugates for Potent Activation of the RIG-I Pathway.
Palmer CR; Pastora LE; Kimmel BR; Pagendarm HM; Kwiatkowski AJ; Stone PT; Arora K; Francini N; Fedorova O; Pyle AM; Wilson JT
Adv Healthc Mater; 2024 Apr; ():e2303815. PubMed ID: 38648653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
